Vasomotor symptoms – Pipeline Insight, 2020

Vasomotor symptoms – Pipeline Insight, 2020

  • November 2020 •
  • 85 pages •
  • Report ID: 5982687 •
  • Format: PDF
“Vasomotor symptoms – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Vasomotor symptoms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Vasomotor symptoms Understanding

Vasomotor symptoms: Overview
Vasomotor symptoms are those that occur due to the constriction or dilation of blood vessels. They include hot flashes, night sweats, heart palpitations, and changes in blood pressure. The most likely reason why these symptoms can occur during menopause is that hormonal fluctuations affect the mechanisms that control blood pressure and temperature control.
Alongside hot flashes, a person may experience:
• Sweating, including night sweats
• Sleep disturbances
• Anxiety
• Heart palpitations
Healthcare providers can consider medical history, risk factors, symptoms, physical examinations, and lab tests when diagnosing Vasomotor symptoms. One may need imaging tests such as a chest x-ray or a CT scan of the lungs or other parts of body depending on the location of the suspected infection. Healthcare providers may also perform a tissue biopsy, in which a small sample of affected tissue is analyzed in a laboratory for evidence of Aspergillus under a microscope or in a fungal culture. A blood test can help diagnose invasive Vasomotor symptoms early in people who have severely weakened immune systems.
A doctor may recommend medication to help people manage hot flashes.
• Hormone therapy: Hormone therapy aims to balance hormone levels in the body. It can help relieve hot flashes and other symptoms, but it is not suitable for everyone, as it can lead to side effects.
• Antidepressants,such as paroxetine (Paxil), may help. A doctor will usually prescribe a lower dosage for menopause symptoms than for depression.

Vasomotor symptoms Emerging Drugs Chapters
This segment of the Vasomotor symptoms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasomotor symptoms Emerging Drugs
• Estetrol: Mithra Pharmaceuticals
Estetrol (E4) is the first NEST: Native Estrogen with Selective action in Tissues. Because of its unique mode of action, Mithra believes E4 has the potential to transform the Women’s Health Market, providing an improved side effect profile over current estrogens in key areas including oral contraception and menopause. Mithra is focused on the development of three late-stage E4-based products: Estelle, a new era in combined oral contraception, PeriNestaTM, the first complete oral treatment for perimenopause and Donesta, a next generation hormone therapy for VMS in menopause. It is currently in phase III stage of development.
• NT-814: NeRRe Therapeutics
NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal vasomotor symptoms (PMVMS).
• MLE-301: Millendo Therapeutics
Millendo Therapeutics is currently advancing the development of MLE-301 for the treatment of vasomotor symptoms (VMS). MLE-301 leverages recent biological insights that elucidated the central regulator of reproductive hormonal signaling, the KNDy (kisspeptin/neurokinin B/dynorphin) neuron. MLE-301 is a potent and reversible antagonist of the human neurokinin 3 receptor, NK3R, and is selective for the NK3 receptor over the NK2 and NK1 receptors. Studies to enable a first-in-human Phase 1 program with MLE-301 are underway.
Further product details are provided in the report……..

Vasomotor symptoms: Therapeutic Assessment
This segment of the report provides insights about the different Vasomotor symptoms drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Vasomotor symptoms
There are approx. 30+ key companies which are developing the therapies for Vasomotor symptoms. The companies which have their Vasomotor symptoms drug candidates in the most advanced stage, i.e. phase III include Mithra Pharmaceuticals and others
• Phases
report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Vasomotor symptoms pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasomotor symptoms: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vasomotor symptoms therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasomotor symptoms drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Vasomotor symptoms R&D. The therapies under development are focused on novel approaches to treat/improve Vasomotor symptoms.
• NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of menopause. NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd a separate legal entity.
Vasomotor symptoms Report Insights
• Vasomotor symptoms Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vasomotor symptoms Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Vasomotor symptoms drugs?
• How many Vasomotor symptoms drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasomotor symptoms?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasomotor symptoms therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vasomotor symptoms and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Mithra Pharmaceuticals
• NeRRe Therapeutics
• Millendo Therapeutics
• Arbor Pharmaceuticals
• Mitsubishi Tanabe Pharma Development America
• Astellas Pharma
• Radius Pharmaceuticals
• Sojournix
• Depomed

Key Products
• Estetrol
• NT-814
• MLE-301
• AR08
• MT-8554
• Fezolinetant
• RAD1901
• SJX-653
• Gabapentin